Biotech Values

[DewDiligence]

At 3/31/12, MNTA’s effective cash balance was $422M; this includes $382.2M of unrestricted cash and marketable securities, $17.5M of restricted cash (in support of the court bond in the Lovenox patent case), and $22M of A/R from Novartis for Lovenox royalties accrued during 1Q12 and paid during 2Q12.